Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV005387311 | SCV006045648 | uncertain significance | Inborn genetic diseases | 2024-12-30 | criteria provided, single submitter | clinical testing | The c.2521A>G (p.I841V) alteration is located in exon 18 (coding exon 17) of the PIK3CA gene. This alteration results from an A to G substitution at nucleotide position 2521, causing the isoleucine (I) at amino acid position 841 to be replaced by a valine (V). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. This missense alteration is located in a region that has a low rate of benign missense variation (Lek, 2016; Firth, 2009). The in silico prediction for this alteration is inconclusive. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004736870 | SCV005345698 | likely pathogenic | PIK3CA-related disorder | 2024-06-08 | no assertion criteria provided | clinical testing | The PIK3CA c.2521A>G variant is predicted to result in the amino acid substitution p.Ile841Val. This variant was reported as de novo in two individuals with developmental disorder or autism (Table S1, Kaplanis et al. 2020. PubMed ID: 33057194; Table S3, Zhou et al. 2022. PubMed ID: 35982159). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as likely pathogenic. |